Loading clinical trials...
Loading clinical trials...
A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated
Conditions
Interventions
Trastuzumab
Cetuximab
+2 more
Locations
48
United States
Kaiser Permanente-Anaheim
Anaheim, California, United States
Kaiser Permanente-Baldwin
Baldwin Park, California, United States
Kaiser Permanente-Bellflower
Bellflower, California, United States
Kaiser Permanente-Fontana
Fontana, California, United States
Kaiser Permanente-Harbor City
Harbor City, California, United States
Kaiser Permanente-Irvine
Irvine, California, United States
Start Date
May 18, 2018
Primary Completion Date
September 30, 2021
Completion Date
September 30, 2022
Last Updated
March 31, 2022
NCT07446322
NCT07536113
NCT07416552
NCT07228832
NCT04657068
NCT06625775
Lead Sponsor
NSABP Foundation Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions